2022-08-012023-07-312023-07-31false13535358AKOMA THERAPY LTD2023-10-0486900iso4217:GBPxbrli:pure135353582022-08-01135353582023-07-31135353582022-08-012023-07-31135353582021-07-28135353582022-07-31135353582021-07-282022-07-3113535358bus:SmallEntities2022-08-012023-07-3113535358bus:AuditExempt-NoAccountantsReport2022-08-012023-07-3113535358bus:AbridgedAccounts2022-08-012023-07-3113535358bus:PrivateLimitedCompanyLtd2022-08-012023-07-3113535358core:WithinOneYear2023-07-3113535358core:AfterOneYear2023-07-3113535358core:WithinOneYear2022-07-3113535358core:AfterOneYear2022-07-3113535358core:ShareCapital2023-07-3113535358core:SharePremium2023-07-3113535358core:RevaluationReserve2023-07-3113535358core:OtherReservesSubtotal2023-07-3113535358core:RetainedEarningsAccumulatedLosses2023-07-3113535358core:ShareCapital2022-07-3113535358core:SharePremium2022-07-3113535358core:RevaluationReserve2022-07-3113535358core:OtherReservesSubtotal2022-07-3113535358core:RetainedEarningsAccumulatedLosses2022-07-3113535358core:LandBuildings2023-07-3113535358core:PlantMachinery2023-07-3113535358core:Vehicles2023-07-3113535358core:FurnitureFittings2023-07-3113535358core:OfficeEquipment2023-07-3113535358core:NetGoodwill2023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-07-3113535358core:ListedExchangeTraded2023-07-3113535358core:UnlistedNon-exchangeTraded2023-07-3113535358core:LandBuildings2022-07-3113535358core:PlantMachinery2022-07-3113535358core:Vehicles2022-07-3113535358core:FurnitureFittings2022-07-3113535358core:OfficeEquipment2022-07-3113535358core:NetGoodwill2022-07-3113535358core:IntangibleAssetsOtherThanGoodwill2022-07-3113535358core:ListedExchangeTraded2022-07-3113535358core:UnlistedNon-exchangeTraded2022-07-3113535358core:LandBuildings2022-08-012023-07-3113535358core:PlantMachinery2022-08-012023-07-3113535358core:Vehicles2022-08-012023-07-3113535358core:FurnitureFittings2022-08-012023-07-3113535358core:OfficeEquipment2022-08-012023-07-3113535358core:NetGoodwill2022-08-012023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2022-08-012023-07-3113535358core:ListedExchangeTraded2022-08-012023-07-3113535358core:UnlistedNon-exchangeTraded2022-08-012023-07-3113535358core:MoreThanFiveYears2022-08-012023-07-3113535358core:Non-currentFinancialInstruments2023-07-3113535358core:Non-currentFinancialInstruments2022-07-3113535358dpl:CostSales2022-08-012023-07-3113535358dpl:DistributionCosts2022-08-012023-07-3113535358dpl:AdministrativeExpenses2022-08-012023-07-3113535358core:LandBuildings2022-08-012023-07-3113535358core:PlantMachinery2022-08-012023-07-3113535358core:Vehicles2022-08-012023-07-3113535358core:FurnitureFittings2022-08-012023-07-3113535358core:OfficeEquipment2022-08-012023-07-3113535358core:NetGoodwill2022-08-012023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2022-08-012023-07-3113535358dpl:GroupUndertakings2022-08-012023-07-3113535358dpl:ParticipatingInterests2022-08-012023-07-3113535358dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-012023-07-3113535358core:ListedExchangeTraded2022-08-012023-07-3113535358dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-012023-07-3113535358core:UnlistedNon-exchangeTraded2022-08-012023-07-3113535358dpl:CostSales2021-07-282022-07-3113535358dpl:DistributionCosts2021-07-282022-07-3113535358dpl:AdministrativeExpenses2021-07-282022-07-3113535358core:LandBuildings2021-07-282022-07-3113535358core:PlantMachinery2021-07-282022-07-3113535358core:Vehicles2021-07-282022-07-3113535358core:FurnitureFittings2021-07-282022-07-3113535358core:OfficeEquipment2021-07-282022-07-3113535358core:NetGoodwill2021-07-282022-07-3113535358core:IntangibleAssetsOtherThanGoodwill2021-07-282022-07-3113535358dpl:GroupUndertakings2021-07-282022-07-3113535358dpl:ParticipatingInterests2021-07-282022-07-3113535358dpl:GroupUndertakingscore:ListedExchangeTraded2021-07-282022-07-3113535358core:ListedExchangeTraded2021-07-282022-07-3113535358dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-07-282022-07-3113535358core:UnlistedNon-exchangeTraded2021-07-282022-07-3113535358core:NetGoodwill2023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-07-3113535358core:LandBuildings2023-07-3113535358core:PlantMachinery2023-07-3113535358core:Vehicles2023-07-3113535358core:FurnitureFittings2023-07-3113535358core:OfficeEquipment2023-07-3113535358core:AfterOneYear2023-07-3113535358core:WithinOneYear2023-07-3113535358core:ListedExchangeTraded2023-07-3113535358core:UnlistedNon-exchangeTraded2023-07-3113535358core:ShareCapital2023-07-3113535358core:SharePremium2023-07-3113535358core:RevaluationReserve2023-07-3113535358core:OtherReservesSubtotal2023-07-3113535358core:RetainedEarningsAccumulatedLosses2023-07-3113535358core:NetGoodwill2022-07-3113535358core:IntangibleAssetsOtherThanGoodwill2022-07-3113535358core:LandBuildings2022-07-3113535358core:PlantMachinery2022-07-3113535358core:Vehicles2022-07-3113535358core:FurnitureFittings2022-07-3113535358core:OfficeEquipment2022-07-3113535358core:AfterOneYear2022-07-3113535358core:WithinOneYear2022-07-3113535358core:ListedExchangeTraded2022-07-3113535358core:UnlistedNon-exchangeTraded2022-07-3113535358core:ShareCapital2022-07-3113535358core:SharePremium2022-07-3113535358core:RevaluationReserve2022-07-3113535358core:OtherReservesSubtotal2022-07-3113535358core:RetainedEarningsAccumulatedLosses2022-07-3113535358core:NetGoodwill2021-07-2813535358core:IntangibleAssetsOtherThanGoodwill2021-07-2813535358core:LandBuildings2021-07-2813535358core:PlantMachinery2021-07-2813535358core:Vehicles2021-07-2813535358core:FurnitureFittings2021-07-2813535358core:OfficeEquipment2021-07-2813535358core:AfterOneYear2021-07-2813535358core:WithinOneYear2021-07-2813535358core:ListedExchangeTraded2021-07-2813535358core:UnlistedNon-exchangeTraded2021-07-2813535358core:ShareCapital2021-07-2813535358core:SharePremium2021-07-2813535358core:RevaluationReserve2021-07-2813535358core:OtherReservesSubtotal2021-07-2813535358core:RetainedEarningsAccumulatedLosses2021-07-2813535358core:AfterOneYear2022-08-012023-07-3113535358core:WithinOneYear2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-012023-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2023-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2022-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-07-3113535358bus:Director12022-08-012023-07-31

AKOMA THERAPY LTD

Registered Number
13535358
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2023

AKOMA THERAPY LTD
Company Information
for the year from 1 August 2022 to 31 July 2023

Director

Carl Barge

Registered Address

71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

Registered Number

13535358 (England and Wales)
AKOMA THERAPY LTD
Balance Sheet as at
31 July 2023

Notes

2023

2022

£

£

£

£

Current assets
Debtors7,619-
Cash at bank and on hand1,9824,060
9,6014,060
Creditors amounts falling due within one year6(2,786)(3,547)
Net current assets (liabilities)6,815513
Total assets less current liabilities6,815513
Net assets6,815513
Capital and reserves
Called up share capital100100
Profit and loss account6,715413
Shareholders' funds6,815513
The financial statements were approved and authorised for issue by the Director on 4 October 2023, and are signed on its behalf by:
Carl Barge
Director
Registered Company No. 13535358
AKOMA THERAPY LTD
Notes to the Financial Statements
for the year ended 31 July 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Accounting policies
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation and operations policy
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
4.Employee information

20232022
Average number of employees during the year00
5.Debtors within one year

2023

2022

££
Trade debtors / trade receivables221-
Other debtors7,398-
Total7,619-
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
6.Creditors within one year

2023

2022

££
Trade creditors / trade payables213253
Taxation and social security2,5733,294
Total2,7863,547
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.